Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

Cummings, J., Schwartz, G. G., Nicholls, S. J., Khan, A., Halliday, C., Toth, P. P., Sweeney, M., Johansson, J. O., Wong, N. C. W., Kulikowski, E., Kalantar-Zadeh, K., Lebioda, K., Ginsberg, H. N., Winblad, B., Zetterberg, H., & Ray, K. K. (2021). Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. Journal of Alzheimer’s Disease, 83(4), 1703–1715. https://doi.org/10.3233/jad-210570
Authors:
Jeffrey Cummings
Gregory G Schwartz
Stephen J Nicholls
Aziz Khan
Chris Halliday
Peter P Toth
Michael Sweeney
Jan O Johansson
Norman C W Wong
Ewelina Kulikowski
Kamyar Kalantar-Zadeh
Kenneth Lebioda
Henry N Ginsberg
Bengt Winblad
Henrik Zetterberg
Kausik K Ray
Affiliated Authors:
Henry N Ginsberg
Columbia Affiliation:
Subjects:
Epigenesis, Genetic (MeSH)
Mental Status and Dementia Tests (MeSH)
Quinazolinones (MeSH)
Author Keywords:
alzheimer’s disease
bet inhibitor
apabetalone
clinical trial
epigenetics
montreal cognitive assessment
elink
Publication Type:
Article
Unique ID:
10.3233/jad-210570
PMID:
34459400
DOI:
10.3233/jad-210570
Journal:
Journal of Alzheimer's Disease
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: